(Q38177173)

30 August 2017

title

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus (English)

1 reference

30 August 2017

0 references

1

Greg L Plosker

1 reference

30 August 2017

publication date

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

223-242

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Mortality attributable to diabetes: estimates for the year 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

New treatments in type 2 diabetes: a focus on the incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0169-1

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

21 January 2018

1 reference

12 December 2020

Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial

1 reference

12 December 2020

Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States

1 reference

12 December 2020

The effects of simvastatin on the pharmacokinectics of sitagliptin

1 reference

12 December 2020

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

1 reference

12 December 2020

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

1 reference

12 December 2020

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

12 December 2020

The association of glycemia and cause-specific mortality in a diabetic population

1 reference

12 December 2020

Glucagon-like peptide 1-based drugs and pancreatic safety

1 reference

12 December 2020

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

1 reference

12 December 2020

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

12 December 2020

10.1007/S40265-013-0169-1

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1008322827

0 references

1 reference